Skip to content
AusGrant
Federal Closing soon GRANTS-GOV-362227

DoW Multiple Sclerosis Clinical Trial Award

Defense Health Agency Contracting Activity - DHACA (DOD) · Competitive grant · Science & Technology

At a glance

DoW Multiple Sclerosis Clinical Trial Award is a federal competitive grant from Defense Health Agency Contracting Activity - DHACA for the science & technology sector. Funding is up to $2K. Eligible applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility". The application deadline is August 13, 2026. Apply via the official listing at www.grants.gov.

Amount
Up to $2K
Deadline
Aug 13, 2026
Type
Competitive
Status
Closing soon

About this program

Summary: The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of multiple sclerosis. All applications must address at least one of the FY26 MSRP CTA focus areas. Clinical trials may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies.Distinctive Features: The FY26 CTA offers two funding levels. The following are generalized descriptions of the scope of research appropriate for each funding level:• Funding Level 1 (CTA-FL1) supports small-scale, proof-of-principle clinical trials (e.g., pilot, first-in-human, phase 0) to demonstrate feasibility or inform the design of more advanced trials, or other clinical trials that are appropriate for this funding level. Preliminary data relevant to the proposed clinical trial are required.• Funding Level 2 (CTA-FL2) supports larger-scale clinical trials at phase 1 or phase 2 that seek to show preliminary evidence of safety or efficacy (i.e., benefit of clinical or paraclinical outcomes) in relevant patient populations. Clear description and justification should be provided, which could include, but is not limited to, the intervention type, trial duration, sample size, outcome measures, assessment tools and frequency of assessment. Preliminary data relevant to the proposed clinical trial in MS populations are required.For the purposes of this funding opportunity, Regulatory Agency refers to the U.S. Food and Drug Administration (FDA) or any relevant international regulatory agency unless otherwise noted.

Who can apply

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

How to apply

Apply through Grants.gov using funding opportunity number HT942526MSRPCTA. Register your organization (SAM.gov + Grants.gov) before the deadline, then submit the application package listed in the official notice.

Apply at official source